Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

Therapeutics & Diagnostics 23-045

Antibody for treatment and diagnosis of Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)

Representative image of thrombosis, which can be caused by VITT.


Tech ID



I. Nazy
N. Ivetic
D. Arnold
J. Kelton
I. A. Kaltashov
D. G. Ivanov

Patent Status

US provisional filed

Stage of Research

Proof of concept available


Amy Hector
Business Development Manager


Vaccine-induced immune thrombotic thrombocytopenia (VITT), causing blood clotting and low platelet counts, has been identified as a reaction to the COVID-19 adenoviral (Ad) vectored vaccines [1]. To allow for sufficient diagnosis and treatment, it is important to elucidate the mechanism of VITT [1].

Researchers at McMaster University and University of Massachusetts Amherst have determined the polypeptide sequence of the variable region for unique anti-platelet factor 4 (PF4) antibodies, which is implicated in VITT [2].


  • Use in the diagnosis and study of VITT, through the detection and measurement of the antibodies.
  • Clinical applications as a treatment method for patients with VITT and potentially heparin-induced thrombocytopenia (HIT).


  • First VITT anti-PF4 antibody to be introduced for this disorder.
  • Discovery can be used in understanding VITT pathology, diagnosis, and potential treatments.


  1. Roytenberg, R., García-Sastre, A. & Li, W. Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto? Frontiers in Medicine 10, (2023).

  2. Nguyen, S. N. et al. Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT). bioRxiv 2023.05.28.542636 (2023) doi:10.1101/2023.05.28.542636.

Image obtained from: